Moderna, Inc. shares rise 2.72% intraday after U.S. FDA independently recommends virus strains for 2025-2026 influenza vaccines.

Moderna, Inc. rose 2.72% intraday. The U.S. FDA's independent recommendations for influenza vaccines and the planned studies on links between autism and environmental toxins by U.S. Health Secretary Robert F. Kennedy Jr. may have positively influenced investor sentiment towards Moderna, Inc.